Toxic epidermal necrolysis (TEN) is a rare but potentially life-threatening complication after haematopoietic stem cell transplantation (HSCT). It is usually provoked by the administration of a drug, and is characterized by extensive skin detachment, erosive mucosal involvement and acute necrosis of the epidermis. TEN shares clinical and histological similarities with grade IV acute graft-versushost disease (aGvHD), pointing to a common pathogenetic pathway. [1] [2] [3] [4] Here, we describe a patient with multiple myeloma who developed severe epidermolysis after allogeneic HSCT. Primary treatment had consisted of four courses of idarubicine/dexamethasone, one course ifosfamide/epirubicin/etoposide and one course melphalan followed by autologous HSCT.
Allogeneic transplantation was undertaken subsequently owing to a high-risk cytogenetic constellation with deletion 13q. After conditioning with melphalan 140 mg m À2 (day À2), fludarabine 30 mg m À2 (day À5 to À3), antithymocyte globulin 10 mg kg À1 (day À3 to À1), 6.21 Â 10 6 kg À1 CD34 þ peripheral blood stem cells from an unrelated human leukocyte antigen-matched male donor were transplanted. GvHD prophylaxis consisted of methotrexate 10 mg m À2 (day þ 1, þ 3, þ 6) and cyclosporine (3 mg kg À1 ) starting at day À1. Twenty-two days after HSCT the patient developed oral ulceration, bilateral conjunctivitis and a generalized maculopapular erythema with multiple blister formation and large areas of epidermal denudation. A skin biopsy was taken from an area without frank clinical epidermal necrosis. On histologic examination, there was observed profound epidermal spongiosis and apoptosis of many keratinocytes preferentially involving basal or intermediate layers of the epidermis, but an inflammatory mononuclear infiltrate indicative of interface dermatitis was largely absent (Figure 1) .
The clinical features and histology were compatible with both aGvHD grade IV and TEN, leading to a diagnostic dilemma. However, TEN owing to an adverse drug reaction rather than aGvHD was favoured because of the absence of gastrointestinal or liver involvement, the lack of cellular infiltration and confluent necrosis, which involved in parts the full thickness of the epidermis.
Evaluation of the causality between drugs administered and TEN was difficult. Some potentially TENinducing drugs had been repeatedly used in this patient during previous therapy cycles without adverse reaction. Therefore, all recently started medications potentially associated with TEN, including trimethoprim-sulphamethoxazole, levofloxacin and amoxicillin/clavulanic acid, were stopped.
The patient was barrier nursed on a special mattress as used in burn units. Local skin care consisted of topical application of silver sulphazidine. Although the use of systemic corticosteroids is controversial, 1 she received methylprednisolone 2 mg kg À1 bodyweight over 14 days with dose tapering afterwards, and immunoglobulins (2 mg kg À1 bodyweight Octagam distributed over 5 days). Her skin improved and re-epithelialization started 1 week after onset of symptoms. After 4 weeks, she had no areas of epidermal denudation but the skin was hyperaemic. The patient recovered fully without any signs of chronic GvHD up to day þ 500.
At that time, relapse of multiple myeloma was diagnosed and treatment with bortezomib, local irradiation of the lumbar spinal column and donor lymphocyte infusion (1.7 Â 10 7 CD3 þ cells) was started. Subsequently the patient developed aGvHD (skin grade II, gut grade III, liver grade I) that differed clinically from the initial picture of TEN. Unfortunately, the patient died 593 days after HSCT owing to severe sepsis with multi-organ failure.
In describing this case, we wish to remind physicians to take into account TEN as a rare differential diagnosis in HSCT patients with extensive skin detachment and necrosis 
